Error message

There was an error processing your request.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 23, 2024 17:33 ET
3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, announced that Mary Beth Cicero, Co-Founder and CEO, will participate in an expert panel to discuss the opportunities in Women’s Health and the disparities...
May 23, 2024 17:30 ET
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced preliminary data from the ongoing...
May 23, 2024 17:30 ET
Premier Health Reports 2024 Second Quarter Results
Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated Financial Statements and MD&A for its second quarter ended on March 31st, 2024....
May 23, 2024 17:30 ET
Titanium Transportation Group Declares Quarterly Dividend
The Board of Directors of Titanium Transportation Group Inc. (“Titanium” or the “Company”) (TSX:TTNM, OTCQX:TTNMF) has declared a quarterly dividend of $0.02 per common share, payable on June 15, 2024 to shareholders of record at the close of...
May 23, 2024 17:29 ET
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024. Altimmune is a...
May 23, 2024 17:25 ET
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $5.50 per share for which Matterport, Inc. (Nasdaq: MTTR) (“Matterport”) has agreed to be sold to CoStar Group (“CoStar”). Under the terms of the deal, Matterport...
May 23, 2024 17:23 ET
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead...
May 23, 2024 17:22 ET
Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
The United Nations Association in Canada (UNA-Canada) is thrilled to announce that our annual gala honouring our Global Citizen Award 2024 Laureate, Manjit Minhas, will be held on October 15 in Toronto. This award recognizes Canadians who have...
May 23, 2024 17:22 ET
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Harbor Diversified, Inc. (OTC: HRBR) securities between May 10, 2022 and March 29, 2024. Harbor...
May 23, 2024 17:21 ET
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Intel Corporation (NASDAQ: INTC) securities between January 25, 2024 and April 25, 2024. Intel designs,...
May 23, 2024 17:18 ET
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a  B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on May 23, 2024, it received a delinquency compliance alert notice...
May 23, 2024 17:15 ET
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2...
May 23, 2024 17:13 ET
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that four abstracts from the company's portfolio will be presented at the 2024 American Society...
May 23, 2024 17:11 ET
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
Special Olympics Florida has announced a new, five-year agreement with Orlando Health, continuing a partnership that first began in 2019. As part of the agreement, Orlando Health will: Serve as a Special Olympics Florida sponsor over the next...
May 23, 2024 17:10 ET
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation...
May 23, 2024 17:09 ET
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
Results will be presented at American Society of Clinical Oncology (ASCO) Annual MeetingMedian overall survival was 20.3 months, nearly doubling the median OS historically observed with standard of care in similar patient populationGSK to support...
May 23, 2024 17:06 ET
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC)...
May 23, 2024 17:05 ET
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May...
May 23, 2024 17:05 ET
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company’s AFM24-102 study in advanced EGFR wild-type (EGFRwt)...
May 23, 2024 17:05 ET
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced expanded data at an upcoming...